Eckert & Ziegler to develop cancer drug for Molecular Insight

10/22/2009 | HealthImaging.com

Molecular Insight Pharmaceuticals has asked German firm Eckert & Ziegler to develop a new cancer drug using its radiotherapeutic compound, Onalta, which is a product candidate for the treatment of some neuroendocrine tumors. Eckert & Ziegler will combine Onalta with the 90Y edotreotide radioisotope to produce the cancer treatment.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN